Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07392190 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Name: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — clinical trial record (NCT07392190)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ENLIGHTEN-6

StatusRecruiting

PhasePhase 3

SponsorEli Lilly and Company

Started2026-02-10

View on ClinicalTrials.gov ↗

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

Amendment history 3 changes detected by DataLookout

2026-08-07

Trial sites expanded: 173 → 188 locations

2026-07-19

Trial sites reduced: 185 → 173 locations

2026-06-24

Trial sites expanded: 180 → 183 locations

Trial Details

NCT Number	NCT07392190
Lead Sponsor	Eli Lilly and Company
Conditions	Overweight, Obesity
Enrollment	900 participants
Start Date	2026-02-10
Primary Completion	2028-06 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-08